Krystal Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell KRYS and other ETFs, options, and stocks.

About KRYS

Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. 

CEO
Krish S. Krishnan
CEOKrish S. Krishnan
Employees
295
Employees295
Headquarters
Pittsburgh, Pennsylvania
HeadquartersPittsburgh, Pennsylvania
Founded
2016
Founded2016
Employees
295
Employees295

KRYS Key Statistics

Market cap
9.31B
Market cap9.31B
Price-Earnings ratio
40.38
Price-Earnings ratio40.38
Dividend yield
—
Dividend yield—
Average volume
255.54K
Average volume255.54K
High today
$318.91
High today$318.91
Low today
$313.83
Low today$313.83
Open price
$318.91
Open price$318.91
Volume
9.11K
Volume9.11K
52 Week high
$382.54
52 Week high$382.54
52 Week low
$183.03
52 Week low$183.03

Stock Snapshot

With a market cap of 9.31B, Krystal Biotech(KRYS) trades at $314.38. The stock has a price-to-earnings ratio of 40.38.

On 2026-10-23, Krystal Biotech(KRYS) stock moved within a range of $313.83 to $318.91. With shares now at $314.38, the stock is trading +0.2% above its intraday low and -1.4% below the session's peak.

Trading activity shows a volume of 9.11K, compared to an average daily volume of 255.54K.

Over the past 52 weeks, Krystal Biotech(KRYS) stock has traded between a high of $382.54 and a low of $183.03.

Over the past 52 weeks, Krystal Biotech(KRYS) stock has traded between a high of $382.54 and a low of $183.03.

KRYS News

Benzinga 14h
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Benzinga

...

Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Benzinga
Zacks 7d
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Krystal Biotech (KRYS Quick QuoteKRYS - Free Report) announced positive clinical data for KB113, its investigational intratumoral immunotherapy being deve...

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Analyst ratings

92%

of 13 ratings
Buy
92.3%
Hold
7.7%
Sell
0%

People also own

Based on the portfolios of people who own KRYS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.